ACM
EBS icon

Anfield Capital Management’s Emergent Biosolutions EBS Stock Holding History

Anfield Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-508
Closed -$11K – 91
2022
Q3 		$11K Buy
508
+18
+4% +$501 0.01% 89
2022
Q2 		$15K Buy
490
+72
+17% +$2.46K 0.01% 91
2022
Q1 		$17K Buy
+418
New +$18.4K 0.01% 93

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Anfield Capital Management's EBS Position: Q4 2022 in Review

Anfield Capital Management sold out of Emergent Biosolutions (EBS) in Q4 2022, closing a stake of 508 shares — an estimated $11K sold.

Anfield Capital Management first reported a position in EBS in Q1 2022 and held it in 3 quarters. The position peaked at $17K in Q1 2022. 198 funds tracked by Wall St. Rank hold EBS as of Q4 2022.

  • Anfield Capital Management reported no remaining Emergent Biosolutions position as of Q4 2022 after selling out during the quarter.
  • Anfield Capital Management sold 508 Emergent Biosolutions shares in Q4 2022, an estimated $11K.
  • Anfield Capital Management first reported a position in Emergent Biosolutions in Q1 2022 and held it in 3 quarters.
  • Anfield Capital Management's Emergent Biosolutions position peaked at $17K in Q1 2022.
  • 198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2022.

Based on Anfield Capital Management's 13F filing for Q4 2022, filed 1 Feb 2023.